Abstract
The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 178-183 |
| Number of pages | 6 |
| Journal | Canadian Journal of Veterinary Research |
| Volume | 82 |
| Issue number | 3 |
| State | Published - Jul 1 2018 |
ASJC Scopus subject areas
- veterinary(all)
Fingerprint Dive into the research topics of 'Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs'. Together they form a unique fingerprint.
Cite this
Bartner, L. R., McGrath, S., Rao, S., Hyatt, L. K., & Wittenburg, L. A. (2018). Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Canadian Journal of Veterinary Research, 82(3), 178-183.